Radiology

Host: James R. Bateman, MD, MPH Guest: Jerome A. Barakos, MD Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM Guest: B. Joy Snider, MD, PhD Guest: Charles P. Vega, MD Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdisciplinary approach. "The ARIA Toolkit: An Interdisciplinary Curriculum" is a comprehensive program designed to equip healthcare professionals with

Guest: Prem Soman, MD, PhD, MASNCGuest: Sarah Cuddy, MD Guest: Angela Dispenzieri, MD Host: Saurabh Malhotra, MD, MPH Guest: Sharmila Dorbala, MD, MPH, FASNC Guest: Yvonne Eisele, PhD Guest: Mazan Hanna, MD Guest: Isabelle Lousada Guest: Ahmad Masri, MD, MS Guest: Melissa Lyle, MD Guest: Mathew Parker, MD Guest: Vasvi Singh, MD, FASNC Guest: Ashutosh Wechalekar, MBBS, MD Guest: David Wolinsky, MD, MASNC Guest: Sasha Zivkovic, MD, PhD

Host: Jonathan D. Schoenfeld, MD, MPhil, MPH Guest: Robert L. Ferris, MD, PhD The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate

Host: Ezra Cohen, MD, FRCPSC, FASCO Guest: Sue S. Yom, MD, PhD The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway

Host: James Galvin, MD, MPH, FANA Guest: Gloria Chiang, MD Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF Guest: Charles P. Vega, MD Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are

Host: James Galvin, MD, MPH, FANA Guest: Gloria Chiang, MD Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising

Guest: Arlene B. Chapman, MD Guest: Matthew B. Lanktree, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

Guest: Jimmy T. Lee, MD Guest: Arlene B. Chapman, MD This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).